Laboratory biosafety measures involving SARS-CoV-2 and the classification as a Risk Group 3 biological agent.

Authors:
Kaufer AM; Theis T; Lau KA; Gray JL; Rawlinson WD.

Journal:
Pathology

Publication Year: 2020

DOI:
10.1016/j.pathol.2020.09.006

PMCID:
PMC7524674

PMID:
33070960

View on PubMed View on PMC View Publisher
Journal Information

Full Title: Pathology

Abbreviation: Pathology

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Pathology

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Related Papers from Same Journal
Evaluation of the influenza and respiratory syncytial virus (RSV) targets in the AusDiagnostics SAR…
Phan T; Tran NYK; Gottlieb T and 2 more (2022) - Transparency Score: 2/6
SARS-CoV-2 viral load dynamics and real-time RT-PCR cycle threshold interpretation in symptomatic n…
Fox-Lewis A; Fox-Lewis S; Beaumont J and 13 more (2021) - Transparency Score: 1/6
Use of emerging testing technologies and approaches for SARS-CoV-2: review of literature and global…
Graham M; Ballard SA; Pasricha S and 8 more (2021) - Transparency Score: 2/6
Head-to-head evaluation on diagnostic accuracies of six SARS-CoV-2 serological assays.
Tan SS; Saw S; Chew KL and 8 more (2020) - Transparency Score: 2/6
Laboratory diagnosis of severe acute respiratory syndrome coronavirus 2.
Gulholm T; Basile K; Kok J and 2 more (2020) - Transparency Score: 2/6
View All Papers from This Journal
Transparency Score
1/6
0.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Conflicts of interest and sources of funding The authors state that there are no conflicts of interest to disclose."

Funding Disclosure
Protocol Registration
Open Access
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025